Wuhan Keqian Biology Discloses Investment in DEKON AGR's Hong Kong IPO

Deep News

02/11

Wuhan Keqian Biology Co.,Ltd. stated on an investor interactive platform that it participated as an investor in the Hong Kong Stock Exchange IPO of Sichuan DEKON AGR at the end of 2023. The company clarified that the investment in DEKON AGR was made to strengthen communication and collaboration with a key client, rather than for short-term selling, repurchasing, or investment returns. Consequently, the investment has been classified as a financial asset measured at fair value through other comprehensive income and is reported under other equity instrument investments. For detailed information, refer to the "Notes to Consolidated Financial Statement Items – 18. Other Equity Instrument Investments" section in the company’s periodic financial reports.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1115366674"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115366674\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115366674?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115366674","market":"other","top_or_hot":-1,"title":"Wuhan Keqian Biology Discloses Investment in DEKON AGR's Hong Kong IPO","media":"Deep News","content":"<p>Wuhan Keqian Biology Co.,Ltd. stated on an investor interactive platform that it participated as an investor in the Hong Kong Stock Exchange IPO of Sichuan DEKON AGR at the end of 2023. The company clarified that the investment in DEKON AGR was made to strengthen communication and collaboration with a key client, rather than for short-term selling, repurchasing, or investment returns. Consequently, the investment has been classified as a financial asset measured at fair value through other comprehensive income and is reported under other equity instrument investments. For detailed information, refer to the \"Notes to Consolidated Financial Statement Items – 18. Other Equity Instrument Investments\" section in the company’s periodic financial reports.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuhan Keqian Biology Discloses Investment in DEKON AGR's Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuhan Keqian Biology Discloses Investment in DEKON AGR's Hong Kong IPO\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2026-02-11 21:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Wuhan Keqian Biology Co.,Ltd. stated on an investor interactive platform that it participated as an investor in the Hong Kong Stock Exchange IPO of Sichuan DEKON AGR at the end of 2023. The company clarified that the investment in DEKON AGR was made to strengthen communication and collaboration with a key client, rather than for short-term selling, repurchasing, or investment returns. Consequently, the investment has been classified as a financial asset measured at fair value through other comprehensive income and is reported under other equity instrument investments. For detailed information, refer to the \"Notes to Consolidated Financial Statement Items – 18. Other Equity Instrument Investments\" section in the company’s periodic financial reports.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"醫藥製造","start_time":0,"source_url":"","article_id":"1115366674","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115366674","pubTimestamp":1770816639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Wuhan Keqian Biology Co.,Ltd. stated on an investor interactive platform that it participated as an investor in the Hong Kong Stock Exchange IPO of Sichuan DEKON AGR at the end of 2023. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159151":"食品","688526":"科前生物","BK0239":"医药制造","02419":"德康农牧","BK1237":"包装食品与肉类"},"translate_title":"武汉科前生物披露投资德康AGR香港IPO","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159151":1,"688526":1,"02419":1,"HEXmain":1},"content_text":"Wuhan Keqian Biology Co.,Ltd. stated on an investor interactive platform that it participated as an investor in the Hong Kong Stock Exchange IPO of Sichuan DEKON AGR at the end of 2023. The company clarified that the investment in DEKON AGR was made to strengthen communication and collaboration with a key client, rather than for short-term selling, repurchasing, or investment returns. Consequently, the investment has been classified as a financial asset measured at fair value through other comprehensive income and is reported under other equity instrument investments. For detailed information, refer to the \"Notes to Consolidated Financial Statement Items – 18. Other Equity Instrument Investments\" section in the company’s periodic financial reports.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}